Wistar scientists have identified a novel therapeutic approach that inhibits the gene KDM5A, which improves immune cell infiltration and attack on tumors. This approach has shown promising results in both in vitro and in vivo studies, including reduced tumor burden and improved survival rates in mice with ovarian cancer.
SourceThe Wistar Institute·JournalCancer Immunology Research·TypeExperimental study·DateJun 21, 2022
Researchers discover that malate dehydrogenase 2 (MDH2) is palmitoylated by ZDHHC18, increasing its activity and promoting mitochondrial respiration. This process sustains ovarian cancer cell proliferation both in vitro and in vivo.
SourceScience China Press·JournalScience China Life Sciences·DateJun 10, 2022
Researchers from Bern and Geneva universities will receive $878,000 in funding to investigate mechanisms of resistance to PARPi inhibitors in BRCA-mutated ovarian cancer. The goal is to develop new targeted therapies to improve survival rates for patients with drug-resistant ovarian cancer.
A Phase 3 clinical trial is investigating the effectiveness of a combination of two immunotherapy drugs, nemvaluekin alfa and pembrolizumab, compared to standard chemotherapy for patients with platinum-resistant ovarian cancer. The trial aims to provide a novel treatment option with better efficacy and safety profiles.
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
New research suggests vitamin D can effectively prevent ovarian cancer by restoring the body's natural defenses. The study found that vitamin D counteracts the process of peritoneal metastasis, which allows cancer cells to spread, and strengthens the barrier effect of mesothelial cells.
SourceNagoya University·JournalMatrix Biology·DateMay 30, 2022
Researchers at HKU have discovered a novel cellular and molecular interaction between cancer cells and tumour-associated macrophages that promote peritoneal metastasis of ovarian cancer. The study reveals that Wnt/b-catenin signalling upregulates the expression of metadherin, which communicates with macrophages through CEACAM1.
SourceThe University of Hong Kong·JournalAdvanced Science·DateMay 16, 2022
A new nanosensor platform uses machine learning to analyze spectral signatures of carbon nanotubes for early detection of ovarian cancer. The approach detects biomarkers and recognizes the cancer itself, offering a promising alternative to traditional methods.
SourceLehigh University·JournalNature Biomedical Engineering·DateMay 16, 2022
A recent study published in Endocrinology found that exposure to a scream sound may lead to diminished ovarian reserve and decreased fertility in female rats. The researchers discovered that the scream sound reduced estrogen and Anti-Mullerian hormone levels, as well as the number and quality of eggs, resulting in smaller litters.
SourceThe Endocrine Society·JournalEndocrinology·DateMay 10, 2022
Celestron NexStar 8SE Computerized Telescope
Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers at Moffitt Cancer Center have discovered that tissue-resident memory T cells are crucial for recognizing tumor cells in ovarian cancer. These T cells arise from circulating T cells and undergo a differentiation process to target cancer cells, providing a potential roadmap for improved immunotherapy options.
SourceH. Lee Moffitt Cancer Center & Research Institute·TypeExperimental study·DateApr 14, 2022
Researchers at UC San Diego found that ovarian cancer tumors activate FAK protein to regulate CD155 expression, creating a shield against immune detection and evading treatment. New molecular targets may boost immune response and lead to new combinatorial strategies for this disease.
SourceUniversity of California - San Diego·JournalProceedings of the National Academy of Sciences·DateApr 11, 2022
Researchers discovered that ovarian cancer tumors evade immune attack by redirecting tryptophan breakdown to the serotonin pathway, increasing NAD+ levels. Blocking this pathway with IDO1 inhibitors can be ineffective due to the adaptation of tumor microenvironments.
SourceUniversity of Chicago Medical Center·JournalScience Translational Medicine·DateMar 16, 2022
Researchers at University of Queensland have identified a genetic basis for the increased risk of epithelial ovarian cancer in women with endometriosis. The study found genes that could be targeted to treat both conditions, increasing understanding and treatment options.
SourceUniversity of Queensland·JournalCell Reports Medicine·TypeData/statistical analysis·DateMar 15, 2022
Aranet4 Home CO2 Monitor
Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.
Researchers at the University of Helsinki discovered that tumour cells in ovarian cancer hide from the body's immune system by interacting with specific gene mutations. Tumours with BRCA1/2 mutations are more effectively targeted by killer T-cells, leading to better patient outcomes.
SourceUniversity of Helsinki·JournalNature Communications·DateFeb 11, 2022
A new symptom management approach, WRITE Symptoms, guides patients to reflect on their symptoms and develop strategies for addressing target symptoms. Both nurse-led and self-directed versions of the tool improved women's sense of control over their symptoms after eight weeks.
SourceUniversity of Pittsburgh·JournalJournal of Clinical Oncology·TypeRandomized controlled/clinical trial·DateFeb 7, 2022
Researchers found trametinib to significantly improve progression-free survival and objective response rate in low-grade serous ovarian carcinoma. The median PFS was 13 months, while the ORR was 26%.
SourceUniversity of Texas M. D. Anderson Cancer Center·JournalThe Lancet·DateFeb 3, 2022
A clinical trial found that trametinib significantly slowed ovarian cancer progression by 13 months and increased treatment response by fourfold compared to standard care. The drug showed promise as a new standard of care for low-grade serous ovarian cancer, a common but difficult-to-treat form of the disease.
SourceUniversity of Edinburgh·JournalThe Lancet·TypeRandomized controlled/clinical trial·DateFeb 3, 2022
Ovarian cancer death rates are predicted to decrease by 17% in the UK and 7% in EU countries in 2022. The main contributor is the long-term use of oral contraceptives, reducing the risk by 40%. Other factors include improved diagnosis, treatment, and advancements in treatments for other cancers.
SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·TypeObservational study·DateJan 25, 2022
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C)
Anker Laptop Power Bank 25,000mAh (Triple 100W USB-C) keeps Macs, tablets, and meters powered during extended observing runs and remote surveys.
Researchers have discovered that ovarian cancer begins with cancerous lesions in the fallopian tube linings of women with BRCA-1 mutations. The study's findings hold promise for predicting which women will develop ovarian cancer years or decades in advance, allowing for early detection and prevention strategies.
SourceCedars-Sinai Medical Center·JournalCell Reports·DateDec 28, 2021
Researchers at Hokkaido University analyzed hundreds of women with ovarian granulosa cell tumors to improve understanding of the disease progression and response to therapy. They found that early-stage tumors rarely spread beyond the ovaries, and fertility-sparing surgery may be considered for younger patients.
SourceHokkaido University·JournalGynecologic Oncology·TypeData/statistical analysis·DateDec 3, 2021
Scientists used single-cell sequencing to analyze over 150,000 cells from 11 tumor samples, discovering novel mechanisms of tumor development and identifying potential targets for therapy. The findings may lead to personalized medicine and improved treatment options for gynecologic cancers.
SourceUNC Lineberger Comprehensive Cancer Center·JournalMolecular Cell·TypeExperimental study·DateDec 2, 2021
The FDA has approved Cytalux, which enables surgeons to identify and remove cancerous lesions with greater precision. In a Phase 3 study, nearly 27% of women with confirmed ovarian cancer found at least one undetected lesion during surgery.
SourceUniversity of Pennsylvania School of Medicine·DateNov 30, 2021
Researchers have developed an assay that uses specific immune-biomarkers to monitor patient survival chances and effectiveness of ovarian cancer treatments. The 'sFIS' assay will enable targeted therapy for each patient, improving treatment outcomes.
SourceKU Leuven·JournalJournal for ImmunoTherapy of Cancer·TypeRandomized controlled/clinical trial·DateNov 18, 2021
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
Researchers discovered that inhibiting a specific signaling pathway can prevent immunotherapy resistance in ovarian cancer, leading to improved tumor responses. This breakthrough has significant clinical implications and will inform a new clinical trial to test the efficacy of this approach.
SourceUniversity of Pittsburgh·JournalScience Advances·TypeExperimental study·DateNov 12, 2021
A recent Ludwig Cancer Research study has identified a crucial cellular interaction that enhances the immune system's ability to destroy cancer cells. The interaction involves antigen-presenting cells (APCs) and T lymphocytes (TILs), which work together to boost and sustain T cell functionality. This discovery opens new avenues for tre...
SourceLudwig Institute for Cancer Research·JournalCancer Cell·DateNov 8, 2021
Scientists at The Wistar Institute discovered that loss of ARID1A function enhances a cellular stress response pathway that promotes survival of cancer cells, making them sensitive to pharmacological inhibition. This finding points to a new therapeutic opportunity for ovarian clear cell carcinomas with ARID1A mutations.
SourceThe Wistar Institute·JournalCancer Research·TypeExperimental study·DateSep 21, 2021
Researchers found that BAK/MCL1 complexes can predict the sensitivity of paclitaxel and MCL1 inhibitors in ovarian cancer. The study suggests that this complex can be used to improve treatment outcomes for patients with ovarian cancer.
SourceHefei Institutes of Physical Science, Chinese Academy of Sciences·JournalCell Death and Disease·DateSep 15, 2021
Garmin GPSMAP 67i with inReach
Garmin GPSMAP 67i with inReach provides rugged GNSS navigation, satellite messaging, and SOS for backcountry geology and climate field teams.
Researchers at the University of Alabama at Birmingham have identified DOT1L as a potential therapeutic target for ovarian cancer. Inhibitors of the DOT1L enzyme showed promise in reducing tumor growth and improving survival rates by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis.
SourceUniversity of Alabama at Birmingham·TypeExperimental study·DateAug 5, 2021
Researchers have discovered a new group of patients who are likely to benefit from PARP inhibitor therapy, which has shown unprecedented success in treating BRCA1/2 mutated cancers. The study identified tumours with epigenetic marks that silenced the RAD51C gene, making them sensitive to PARP inhibitors.
SourceWalter and Eliza Hall Institute·JournalCancer Research·TypeExperimental study·DateJul 29, 2021
Researchers at Texas A&M University have developed an organ-on-a-chip that models the interaction between platelets and ovarian cancer tumors, revealing a crucial genetic signaling pathway. This breakthrough technology has potential applications in observing how cancer cells interact with blood vessels and testing novel treatments.
SourceTexas A&M University·JournalScience Advances·DateJul 23, 2021
Researchers recreated ovarian follicle structures using mouse embryonic stem cells and successfully matured primordial germ cells into fully functional oocytes. The study provides a model system for studying later events of oogenesis and has implications for assisted reproductive technologies.
SourceAmerican Association for the Advancement of Science (AAAS)·JournalScience·DateJul 15, 2021
Fluke 87V Industrial Digital Multimeter
Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.
A world-first AI study will map genetic and physical risks of ovarian cancer based on UK Biobank data. The project aims to identify biomarkers for early detection and improve survival rates.
A new assessment tool has been found to predict ovarian damage in girls with cancer, helping doctors determine which patients should undergo fertility preservation. The Edinburgh selection criteria identify high-risk patients who are more likely to develop premature ovarian failure.
SourceEuropean Society of Human Reproduction and Embryology·JournalHuman Reproduction·DateJun 29, 2021
A recent study found that women previously infected with COVID-19 have similar ovarian reserve and fertility treatment outcomes compared to those without a history of the virus. The study monitored hormone levels in 46 patients undergoing IVF in Spain between May and June 2020, revealing no variation in anti-Mullerian hormone (AMH) lev...
SourceEuropean Society of Human Reproduction and Embryology·DateJun 28, 2021
Ovarian cancer is the most lethal gynaecological cancer with an absence of screening programmes, leading to late diagnosis and poor prognosis. Despite targeted therapies, personalized medicine remains a challenge due to inconsistent symptoms and resistance to chemotherapy.
SourceEuropean Society for Medical Oncology·DateJun 21, 2021
Apple Watch Series 11 (GPS, 46mm)
Apple Watch Series 11 (GPS, 46mm) tracks health metrics and safety alerts during long observing sessions, fieldwork, and remote expeditions.
A new study published in Proceedings of the National Academy of Sciences suggests that surgery should precede chemotherapy for certain patients with ovarian cancer. The research used a mathematical model to examine treatment outcomes and found that complete debulking surgery followed by chemotherapy provides better results. For patient...
SourceNYU Langone Health / NYU Grossman School of Medicine·JournalProceedings of the National Academy of Sciences·DateJun 14, 2021
A new radiopharmaceutical has been developed to treat ovarian cancer, dramatically limiting tumor growth and decreasing tumor mass. The treatment, which can be produced in just 25 minutes at low cost, shows promise as an efficient alternative to existing methods.
SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateJun 11, 2021
Researchers from NUS Cancer Science Institute have discovered a link between high levels of DNA repair protein RAD51 and platinum chemotherapy resistance in ovarian cancer patients. This finding could help identify patients who may require novel immunotherapy approaches to improve treatment outcomes.
SourceNational University of Singapore·JournalEMBO Molecular Medicine·DateMay 26, 2021
A large-scale trial of annual screening for ovarian cancer found that neither method reduced deaths from the disease, contradicting expectations. Early detection strategies detected cancers earlier, but this did not translate into saving lives.
SourceUniversity College London·JournalThe Lancet·DateMay 13, 2021
A study published in Nature Communications found that rucaparib is effective in treating ovarian cancers with inherited or somatic mutations in DNA repair genes. The drug targets the Achilles heel of cancers with defects in DNA repair, outperforming chemotherapy in early treatment stages.
SourceUniversity of Washington School of Medicine/UW Medicine·JournalNature Communications·DateMay 3, 2021
Meta Quest 3 512GB
Meta Quest 3 512GB enables immersive mission planning, terrain rehearsal, and interactive STEM demos with high-resolution mixed-reality experiences.
A new study published in Diagnostics demonstrates that artesunate, a drug synthesized from Artemisia annua, kills ovarian cancer cells. The researchers found anticancer activity at achievable concentrations, supporting the clinical development of this strategy.
SourceUniversity of Kentucky·JournalDiagnostics·DateApr 26, 2021
The UK Markey Cancer Center has launched a clinical trial to evaluate the anti-cancer activity of ArtemiLife coffee products in preventing ovarian cancer recurrence. Participants will drink coffee up to four times daily for five months after completing treatment, aiming to delay or eliminate cancer return.
A recent study found that end-of-life care for people with ovarian cancer has not improved significantly since 2007, with Black patients experiencing higher rates of emergency department visits and intensive treatment. Palliative care recommendations have been included in guidelines, but its adoption remains limited.
SourceMichigan Medicine - University of Michigan·JournalCancer·DateApr 5, 2021
A new pilot study suggests that administering platelet-rich plasma and gonadotropins near the ovarian follicles can restore ovarian function in women during early menopause. The results show that 11 out of 12 participants resumed menstruation, with one achieving clinical pregnancy.
SourceThe Menopause Society·JournalMenopause·DateMar 31, 2021
DJI Air 3 (RC-N2)
DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.
Golfers Against Cancer funds three CU Cancer Center researchers: Matthew Sikora studying genetic predispositions to ovarian cancer, Jamie Studts exploring lung cancer screening access, and Jenna Sopfe developing a standardized approach to sexual dysfunction in pediatric cancer survivors.
SourceUniversity of Colorado Anschutz Medical Campus·DateMar 15, 2021
Researchers assessed tumor cell isolation and in vitro proliferation assays to predict chemotherapy response in ovarian cancer. In 12 of 14 cases, in vitro drug sensitivity correlated with clinical outcome.
SourceImpact Journals LLC·JournalOncotarget·DateMar 8, 2021
A study by Queen Mary University researchers investigated how women at high risk of ovarian cancer make choices about possible preventive surgery. Women who have BRCA1 and BRCA2 genetic mutations have a higher lifetime risk of ovarian cancer, and may choose to undergo surgery to reduce their risk.
SourceQueen Mary University of London·JournalJournal of Medical Genetics·DateFeb 10, 2021
A new study from the University of Minnesota Medical School found that Pap test samples can detect proteins also present in ovarian cancer tumor tissues. This discovery suggests potential biomarker candidates for early detection of ovarian cancer, which currently has no early warning system.
SourceUniversity of Minnesota Medical School·JournalClinical Proteomics·DateFeb 9, 2021
Researchers found that antibodies produced by B cells predominantly have the IgA subtype, which inhibits RAS signaling, sensitizing tumor cells to T cell-mediated killing. This study provides insights into how immune components regulate ovarian cancer progression and offers new approaches for targeted immunotherapies.
SourceH. Lee Moffitt Cancer Center & Research Institute·JournalNature·DateFeb 3, 2021
Sky-Watcher EQ6-R Pro Equatorial Mount
Sky-Watcher EQ6-R Pro Equatorial Mount provides precise tracking capacity for deep-sky imaging rigs during long astrophotography sessions.
Ovarian clear cell carcinoma (OCCC) remains a rare subtype with poor prognosis. Simvastatin efficiently controlled OCCC proliferation and migration, demonstrating potential as a candidate drug.
SourceImpact Journals LLC·JournalOncotarget·DateFeb 1, 2021
This study elucidates the molecular mechanism of 2-methoxyestradiol (2MeOE2) inducing apoptosis in ovarian tumors through PKCδ signaling. The findings suggest that 2MeOE2 activates PKCδ, leading to γH2Ax expression and apoptotic histone modifications, thereby driving apoptosis in ovarian cancer cells.
SourceImpact Journals LLC·JournalOncotarget·DateFeb 1, 2021
Researchers discovered that ovarian cancer cells undergo structural changes in their mitochondria to survive and proliferate in the peritoneal cavity. This adaptation enables aggressive cancerous cells to grow and spread, making it harder to detect and treat. Understanding these cellular adaptations could lead to new targeted therapies.
SourceFrontiers·JournalFrontiers in Oncology·DateJan 13, 2021
Mutations in the ARID1A gene increase glutamine metabolism in ovarian cancer cells, which can be blocked to target ARID1A-mutant tumors. Glutaminase inhibitors like CB-839 show promise as a standalone or combination therapy for clear cell ovarian carcinoma.
SourceThe Wistar Institute·JournalNature Cancer·DateJan 11, 2021
Apple MacBook Pro 14-inch (M4 Pro)
Apple MacBook Pro 14-inch (M4 Pro) powers local ML workloads, large datasets, and multi-display analysis for field and lab teams.
A retrospective study of patients with ovarian torsion found that older age, larger ovarian size, and gynecologic oncologist performance were linked to increased oophorectomy rates. The study suggests that surgeon ability to diagnose necrosis is poor, and patient race does not impact the likelihood of oophorectomy.
SourceBoston University School of Medicine·JournalJournal of Gynecologic Surgery·DateDec 18, 2020
A comprehensive study of over 250,000 women found oral contraceptives significantly reduce the risk of ovarian and endometrial cancer, with benefits persisting even years after use ends. The findings contradict previous associations with increased breast cancer risk.
SourceUppsala University·JournalCancer Research·DateDec 17, 2020
Women with frozen eggs and ovarian tissue had more children after breast cancer diagnosis compared to those without fertility preservation. The study highlights the importance of reproductive counseling for young breast cancer patients.
SourceKarolinska Institutet·JournalJAMA Oncology·DateNov 19, 2020
A new study published in JNCI: Journal of the National Cancer Institute indicates that receiving assisted reproductive technology does not increase the risk women have for developing ovarian cancer. While fertility treatments may slightly increase borderline ovarian tumor risk, this association appears to be due to underlying patient c...
Scientists have created a 3D tumour model for ovarian cancer, which can mimic the way tumour cells grow and respond to chemotherapy drugs. The new model has the potential to improve understanding and treatment of the disease.
SourceUniversity of Nottingham·JournalScience Advances·DateOct 2, 2020
GoPro HERO13 Black
GoPro HERO13 Black records stabilized 5.3K video for instrument deployments, field notes, and outreach, even in harsh weather and underwater conditions.
A study from Karolinska Institutet in Sweden found that women receiving fertility-sparing surgery for treatment of borderline ovarian tumours were able to have children, with most preserving natural fertility. The study also showed similar survival rates as those who underwent radical surgical cancer treatment.
SourceKarolinska Institutet·JournalFertility and Sterility·DateSep 25, 2020
Researchers from CU published a paper on ovarian cancer tumor composition changes during chemotherapy, revealing potential biomarkers for therapeutic response. The team aims to improve prediction of patient response to chemotherapy using multi-spectral immunohistochemistry and transcriptomics.
SourceUniversity of Colorado Anschutz Medical Campus·JournalClinical Cancer Research·DateSep 15, 2020